NCT04842812View on ClinicalTrials.gov

Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

December 31, 2029

Study Completion Date

January 1, 2035

Conditions
Liver CancerLung CancerBreast CancerColo-rectal CancerBrain TumorSolid Tumor, AdultPD1CTLA4
Interventions
BIOLOGICAL

TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3

TILs and CAR-TILs injection: 1-10×10e7/kg cells for each treatment; 3 or more cycles.

Trial Locations (1)

510260

RECRUITING

Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
collaborator

Guangdong Zhaotai InVivo Biomedicine Co. Ltd.

OTHER

lead

Second Affiliated Hospital of Guangzhou Medical University

OTHER